GLP-1 for Weight Loss: Semaglutide, Tirzepatide, and What Comes Next

GLP-1 receptor agonists cause weight loss by mimicking glucagon-like peptide-1, a gut hormone that reduces appetite, slows gastric emptying and quiets the constant pull toward food. In the trials that led to FDA approval, weekly semaglutide 2.4 mg (Wegovy) produced 14.9% average body weight loss at 68 weeks, tirzepatide 15 mg (Zepbound) produced 20.9% at 72 weeks, and in SURMOUNT-5, the first head-to-head trial, tirzepatide beat semaglutide by 20.2% to 13.7% (Aronne et al., NEJM 2025).

How GLP-1 Receptor Agonists Actually Work

Glucagon-like peptide-1 (GLP-1) is a hormone your gut releases after you eat. It tells your pancreas to produce insulin, slows gastric emptying so food moves through your stomach more slowly, and sends satiety signals to appetite centers in your brain. In people without obesity, this system works smoothly. You eat, GLP-1 rises, and you eventually feel full.

GLP-1 receptor agonists are synthetic versions of this hormone, engineered to last much longer in the body. Natural GLP-1 breaks down within minutes. Semaglutide, by contrast, has a half-life of about a week, which is why it works as a once-weekly injection [1].

But the weight loss effects go beyond just mimicking a gut hormone. These drugs act directly on the hypothalamus and brainstem, reducing what researchers call “food noise,” the near-constant mental preoccupation with eating that many people with obesity describe. Patients frequently report that they simply stop thinking about food between meals, which is a qualitative change that calorie counting and willpower cannot replicate [2].

There is also growing evidence that GLP-1 agonists reduce the rewarding properties of food. Functional MRI studies show decreased activation in brain reward centers when patients on semaglutide view images of highly palatable foods. This same mechanism appears to explain early reports of reduced alcohol and nicotine cravings in some patients, though those applications remain investigational.

What is the difference between GLP-1, GIP and triple agonists?

The drug class is now defined by how many hormone receptors a molecule activates. Liraglutide (Saxenda) and semaglutide (Wegovy, Ozempic, Rybelsus) activate the GLP-1 receptor alone. Tirzepatide (Zepbound, Mounjaro) is a dual GIP and GLP-1 receptor agonist, sometimes called a “twincretin.”

Retatrutide adds the glucagon receptor, which raises energy expenditure and targets liver fat, making it a triple agonist. Orforglipron (Foundayo) is different in form rather than target: it is a small molecule GLP-1 receptor agonist taken as a daily pill. All of these medicines are sometimes grouped as incretin-based therapies or, informally, as “GLP-1s.”

Semaglutide: The STEP Trial Data

Semaglutide is marketed as Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). The weight loss doses are higher: Wegovy goes up to 2.4 mg weekly, while Ozempic maxes out at 2.0 mg.

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program provides the strongest evidence base:

• STEP 1: 1,961 adults without diabetes. Semaglutide 2.4 mg produced 14.9% body weight loss versus 2.4% with placebo at 68 weeks [3].
• STEP 2: In patients with type 2 diabetes, weight loss was somewhat lower at 9.6%, consistent with the known difficulty of losing weight when insulin resistance is present.
• STEP 3: Combined with intensive behavioral therapy, semaglutide produced 16% body weight loss.
• STEP 5: A two-year extension showing sustained weight loss of 15.2% at 104 weeks, demonstrating durability as long as treatment continues.

To put this in context: a person weighing 250 pounds could expect to lose roughly 37 pounds on semaglutide. That’s meaningful. It’s in the range where metabolic parameters like blood pressure, lipids, HbA1c, and liver fat begin to improve substantially.

The SELECT trial added cardiovascular outcome data, showing a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with obesity and established cardiovascular disease, independent of diabetes status [4]. This was a landmark finding because it established that the cardiovascular benefits were not simply a downstream effect of blood sugar control.

The FDA added a cardiovascular risk reduction indication to Wegovy in March 2024 on the strength of SELECT. Semaglutide also has trial data in knee osteoarthritis: in STEP 9, adults with obesity and knee pain lost 13.7% of body weight versus 3.2% with placebo over 68 weeks and reported less pain on the WOMAC scale [13]. Readers weighing joint options can compare this with the broader osteoarthritis treatment landscape.

Tirzepatide: The Dual Agonist Advantage

Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight management) targets two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism appears to produce greater weight loss than GLP-1 alone.

The SURMOUNT trial program tells the story:

• SURMOUNT-1: 2,539 adults without diabetes. At the highest dose (15 mg), tirzepatide produced 20.9% body weight loss at 72 weeks versus 3.1% with placebo [5]. That’s a 50-pound loss for a 250-pound person.
• SURMOUNT-2: In patients with type 2 diabetes, the highest dose produced 14.7% weight loss.
• SURMOUNT-3: Combined with intensive lifestyle intervention, weight loss reached 26.6% at the top dose.

These numbers approach what bariatric surgery delivers, which has been the benchmark for decades. Roux-en-Y gastric bypass typically produces 25-30% total body weight loss, and sleeve gastrectomy about 20-25%.

Head-to-head data now exists. In SURMOUNT-5, 751 adults with obesity and without diabetes were randomized to the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks, and average weight loss was 20.2% with tirzepatide versus 13.7% with semaglutide [11]. Whether this translates to greater cardiovascular benefit is being tested in ongoing trials.

Tirzepatide also carries a second weight-related indication. The FDA approved Zepbound in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity, after the SURMOUNT-OSA trials showed the apnea-hypopnea index fell by roughly 25 to 29 events per hour at 52 weeks [14]. Weight loss is one part of sleep apnea treatment, alongside CPAP and oral appliances.

Semaglutide vs. Tirzepatide: How Much Weight Do People Lose?

Average weight loss on GLP-1 medications ranges from about 10% to 21% of starting body weight over 68 to 72 weeks, depending on the drug, the dose and whether the person has type 2 diabetes. Tirzepatide produces more weight loss than semaglutide on average, and both outperform the older daily injection liraglutide.

The table collects the main trial results already cited in the sections above. Trial averages hide wide individual variation: some participants lost little, while others lost more than 25%.

For a deeper side-by-side on dosing, side effects and switching, see our semaglutide versus tirzepatide comparison.

Injectable vs. Oral: Where Things Stand

Most people start on weekly subcutaneous injections using an auto-injector pen. The needle is small and the injection is straightforward, but needle aversion is real and it remains a barrier for some patients.

Oral semaglutide (Rybelsus) is available for diabetes, and a higher-dose oral semaglutide tablet for weight management was approved by the FDA as Wegovy tablets in December 2025. The challenge is bioavailability: oral semaglutide must be taken on an empty stomach with a small sip of water, then nothing to eat or drink for 30 minutes. Even under perfect conditions, only about 1% of the drug is absorbed, which is why the tablet doses are much larger than the injected ones.

Orforglipron, a non-peptide oral GLP-1 agonist from Eli Lilly, takes a different route. Because it’s a small molecule rather than a peptide, it doesn’t face the same absorption limitations and has no food or water restrictions. Phase 2 data showed roughly 14.7% weight loss at 36 weeks [6]. In the phase 3 ATTAIN-1 trial, the highest dose produced 11.2% average weight loss at 72 weeks versus 2.1% with placebo [12], and the FDA approved it as Foundayo on April 1, 2026, according to an FDA press announcement.

The practical tradeoff is clear from the trials. Pills remove the needle and simplify storage, but the average weight loss in ATTAIN-1 was smaller than with injectable semaglutide or tirzepatide, and a daily pill asks for daily adherence where an injection asks for one dose a week.

How Are GLP-1 Doses Increased, and How Long Until It Works?

GLP-1 medications start at a low dose and step up every four weeks, a process called titration, so the gut can adapt and nausea stays manageable. Weekly semaglutide reaches its 2.4 mg maintenance dose after 16 weeks, and tirzepatide reaches 15 mg after at least 20 weeks if each step is tolerated. The schedules below follow the FDA prescribing information for Wegovy and Zepbound.

Appetite usually changes within the first few weeks, but meaningful weight loss builds slowly because the early doses are low. In STEP 1 and SURMOUNT-1, average weight kept falling for roughly the first 60 weeks before leveling off. A plateau after that point is expected biology rather than failure,, and clinicians usually respond by reviewing protein intake, training and dose rather than stopping the drug.

Prescribers can hold or slow a step when side effects are strong. Staying on a lower dose longer is common, and many people reach their goals without ever taking the top dose.

Side Effects: What to Expect and What to Watch For

The most common side effects are gastrointestinal, and they’re directly related to the mechanism of action. Slowing gastric emptying means food sits in the stomach longer, which can cause:

• Nausea (40-50% of patients, typically worst during dose titration)
• Vomiting (about 25%)
• Diarrhea (about 30%)
• Constipation (about 25%)

These effects are dose-dependent and usually improve over time. The slow dose-escalation schedule (starting at 0.25 mg and increasing every 4 weeks) exists specifically to minimize GI symptoms. Most patients find them manageable after the first 2-3 months.

Smaller meals, stopping at the first sign of fullness, limiting greasy and very sweet foods, and drinking fluids between meals rather than with them are the adjustments clinicians most often suggest. Persistent vomiting can cause dehydration and kidney strain, so it is a reason to call the prescriber rather than push through.

More serious concerns include:

• Gastroparesis-like symptoms: In a small percentage of patients, gastric emptying slows dramatically, causing severe nausea, vomiting, and abdominal pain that persists even after stopping the medication. Case reports have documented this, though large-scale incidence data is limited.
• Pancreatitis: A theoretical risk based on the mechanism. Clinical trial data has not shown a statistically significant increase, but patients with a history of pancreatitis should avoid these medications [7].
• Gallbladder disease: Rapid weight loss from any cause increases gallstone risk. GLP-1 agonists also directly affect gallbladder motility. The STEP trials showed a 2-3x increase in gallbladder-related events.
• Thyroid concerns: Animal studies showed increased medullary thyroid cancer in rodents at very high doses. This has not been observed in humans, but the drugs carry a boxed warning and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Two practical points round out the safety picture. Because these drugs slow stomach emptying, anesthesiologists may ask patients to pause or adjust them before surgery or endoscopy. Tirzepatide can also reduce the effectiveness of oral contraceptives during dose increases, so the label advises a backup method for four weeks after starting and after each dose step. Report any new or severe symptom to the prescriber rather than waiting for the next scheduled visit.

The Muscle Mass Problem

This is the concern that doesn’t get enough attention. When you lose weight through any method, roughly 25-40% of the weight lost is lean mass (muscle, bone, water) rather than fat. With GLP-1 agonists, the ratio appears similar, and in some studies it may be worse because the appetite suppression is so strong that patients eat inadequately [8].

Losing muscle matters. Muscle is your primary glucose disposal tissue, the main driver of resting metabolic rate, and a critical determinant of functional capacity as you age. Losing 30 pounds is counterproductive if 12 of those pounds are muscle.

Mitigation strategies supported by evidence:

• Protein intake: Target 1.2-1.6 g per kg of body weight daily, with at least 30 g per meal. This is challenging when appetite is suppressed, and protein supplements or high-protein snacks may be necessary.
• Resistance training: 2-3 sessions per week of progressive resistance exercise. This is probably the single most important thing you can do while on a GLP-1 agonist.
• Adequate caloric intake: Some patients on GLP-1 agonists eat as few as 800-1,000 calories daily, which is too low to preserve muscle. Working with a dietitian to maintain a moderate deficit (rather than an extreme one) is worthwhile.
• Creatine supplementation: 3-5 g daily supports muscle protein synthesis and exercise performance during caloric restriction.

Older adults and anyone starting with low muscle mass have the least margin to lose. A body composition scan such as DEXA before and during treatment shows whether the weight coming off is mostly fat, and our GLP-1 muscle loss guide goes deeper on training and protein targets.

Who Is a Good Candidate?

FDA-approved indications for the weight management formulations (Wegovy, Zepbound) include adults with:

• BMI of 30 or higher (obesity), or
• BMI of 27 or higher (overweight) with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea

Beyond the formal criteria, better candidates tend to be people who have tried lifestyle modifications but have strong biological drivers of overeating, such as persistent hunger despite adequate meals, food preoccupation, or a family history of obesity that suggests a genetic predisposition.

Poor candidates include those looking to lose vanity weight (5-10 pounds), people with a history of medullary thyroid carcinoma, those with active pancreatitis or severe gastroparesis, and people who are unwilling to commit to long-term use, given the weight regain data.

Pregnancy is another firm exclusion: the labels advise stopping semaglutide at least two months before a planned pregnancy. People with polycystic ovary syndrome often fit the BMI criteria and have insulin resistance as a driver, which is why GLP-1 use in PCOS is an active area of off-label prescribing.

Who Prescribes GLP-1 Medications?

Any licensed prescriber can write a GLP-1 prescription, including primary care physicians, endocrinologists, obesity medicine physicians, nurse practitioners and physician assistants. Obesity medicine physicians are often board certified by the American Board of Obesity Medicine, and endocrinologists are the usual referral when diabetes, thyroid disease or PCOS is part of the picture.

Prescriptions also come from bariatric surgery programs, telehealth services, and cash pay integrative, functional and medical weight loss clinics. Those clinics often pair GLP-1 programs with nutrition coaching, body composition testing and other peptides, and some prescribe compounded versions rather than branded pens.

Whatever the setting, a careful prescriber takes a medical and family history (including thyroid cancer and pancreatitis), orders baseline labs, explains the titration plan, and schedules follow-up visits to adjust the dose and watch for muscle loss. Registered dietitians and exercise professionals round out the team in well run programs.

How to find a GLP-1 clinic near you

Regenerated.com lists clinics nationally under peptide therapy clinics in the US; check each profile for semaglutide or tirzepatide, who prescribes, and whether the clinic uses branded or compounded medication. Listing order is not paid ranking, Featured slots are labeled and capped, and Verified means credential checks rather than spend. Regenerated.com is free for patients, and inclusion in the directory is not an endorsement, as our guide to Featured, Verified and organic listings explains.

Cost and Insurance: The Uncomfortable Reality

At list price, Wegovy and Zepbound cost roughly $1,000-1,300 per month. Insurance coverage is inconsistent. Many employer-sponsored plans have added coverage, while others exclude weight loss drugs entirely, and Medicaid coverage varies by state. Medicare coverage changed in 2026, as described below.

Manufacturer savings programs can reduce costs for commercially insured patients, and both manufacturers now sell self-pay versions directly to patients at prices well below list, but the out-of-pocket burden remains significant for many people. This has created enormous demand for compounded versions of semaglutide and tirzepatide, which can cost $150-400 per month.

Does Medicare cover GLP-1 drugs for weight loss?

Medicare now covers certain GLP-1 drugs for weight management through the Medicare GLP-1 Bridge, a temporary CMS program running from July 1, 2026, through December 31, 2027. According to Medicare.gov, it covers Foundayo, Wegovy (injection or tablet) and the Zepbound KwikPen for eligible people with Part D coverage, with prior authorization and a $50 monthly copay. Separately, Part D plans can cover Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea.

Compounded semaglutide and tirzepatide

The compounding pharmacy situation is complicated. During drug shortages, the FDA allowed compounding pharmacies to produce semaglutide and tirzepatide. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, and its statement on GLP-1 compounding policy set end dates for the grace periods that followed. Since then, the legal basis for compounding essentially copies of these drugs has narrowed, and the brand manufacturers have pushed back aggressively.

Quality control at compounding pharmacies is also more variable than at major pharmaceutical manufacturing facilities. Compounded GLP-1 products are not FDA approved, are not reviewed for safety or effectiveness, and have been linked to dosing errors when people measure from multi-dose vials. Patients using compounded versions should ensure their pharmacy is accredited by the PCAB or state board of pharmacy. Our treatment guides to compounded semaglutide and compounded tirzepatide cover what to ask a prescriber.

What Happens When You Stop?

This is the question many patients don’t ask early enough. The STEP 1 extension trial showed that participants who stopped semaglutide after 68 weeks regained roughly two-thirds of their lost weight over the following year [9]. Appetite returned to baseline, food noise came back, and the biological drive to eat reasserted itself.

This isn’t a failure of willpower. Obesity involves long-term changes to appetite-regulating hormones, gut microbiota, and brain reward circuitry. A 68-week drug course doesn’t reset those systems permanently, just as stopping blood pressure medication doesn’t make hypertension go away.

The practical implication is that GLP-1 agonists, for most people, are a long-term or indefinite treatment. Some patients can taper to a lower maintenance dose once they reach their goal weight, and there’s interest in intermittent dosing strategies, but the evidence base for these approaches is thin. If you’re considering starting a GLP-1 agonist, go in with the expectation that you may need to stay on it.

The same extension found that blood pressure, blood sugar and other cardiometabolic gains also drifted back toward baseline after stopping. Anyone who stops should keep the resistance training and protein habits built during treatment, since preserved muscle is one of the few gains that does not depend on staying on the drug.

What’s Coming Next

The pipeline is crowded and competitive. The most interesting agents:

• Retatrutide (Eli Lilly): A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data showed up to 24.2% body weight loss at 48 weeks, and the phase 3 TRIUMPH trials have since reported results [10]. The glucagon receptor component may provide additional benefits for liver fat reduction. It is not FDA approved as of November 2026, and products sold online as research-grade retatrutide are not approved drugs. See our retatrutide treatment guide for the current evidence.
• Survodutide (Boehringer Ingelheim): A GLP-1/glucagon dual agonist showing particular promise for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), with significant reductions in liver fat content.
• Orforglipron (Eli Lilly): The oral non-peptide GLP-1 agonist mentioned earlier, approved by the FDA as Foundayo in April 2026, which removes the need for injections for people who respond to it.
• Amycretin (Novo Nordisk): A GLP-1/amylin dual agonist. Phase 1 data showed 13% weight loss in just 12 weeks, suggesting potentially faster onset than current options.

The direction is clear: multi-receptor agonists that produce greater weight loss with potentially fewer side effects, in both injectable and oral formulations.

Optimizing Lifestyle While on a GLP-1 Agonist

These drugs work best as part of a broader strategy, not as a standalone solution. Practical recommendations for patients currently on GLP-1 therapy:

• Prioritize protein at every meal. When your appetite is suppressed and you’re only eating 1,200-1,500 calories, every bite needs to count. Lean meats, fish, eggs, Greek yogurt, and protein supplements should be the foundation of your diet.
• Strength train consistently. This is non-negotiable for preserving muscle mass. Even 2 sessions per week of full-body resistance training makes a measurable difference.
• Stay hydrated. Reduced food intake means less water from food. Many patients on GLP-1 agonists become mildly dehydrated without realizing it.
• Monitor for nutrient deficiencies. Lower food intake means lower micronutrient intake. A daily multivitamin and periodic blood work (vitamin D, B12, iron, magnesium) is reasonable.
• Don’t skip meals. Even if you’re not hungry, eating small, protein-rich meals at regular intervals supports muscle preservation and prevents the binge-restrict cycle.

GLP-1 agonists are powerful tools. They work through real biological mechanisms, produce clinically meaningful weight loss, and improve cardiometabolic outcomes. But they are not magic, and they work far better when combined with the foundational behaviors that support metabolic health long-term: resistance training, adequate protein, quality sleep, and stress management.

Many clinics that prescribe GLP-1 medications offer this support as part of a broader peptide therapy program, with dietitian visits and body composition checks built in. Ask what is included before you commit, and whether follow-up continues after the first few months.

Frequently asked questions

How much weight can you lose on a GLP-1?

Most people lose about 10% to 21% of their starting body weight over 68 to 72 weeks, depending on the drug and dose. In STEP 1, semaglutide 2.4 mg produced 14.9% average weight loss, and in SURMOUNT-1, tirzepatide 15 mg produced 20.9%. People with type 2 diabetes tend to lose less, and individual results vary widely: some lose very little, while others lose more than a quarter of their body weight.

How long does it take for semaglutide or tirzepatide to start working?

Appetite usually drops within the first few weeks, but steady weight loss takes months because doses start low and rise every four weeks. Semaglutide reaches its 2.4 mg maintenance dose at week 17, and tirzepatide can take 20 weeks or more to reach 15 mg. In the major trials, average weight kept falling for roughly the first 60 weeks before leveling off, so judging results at one or two months is too early.

Is tirzepatide better than semaglutide for weight loss?

Tirzepatide produces more weight loss on average. In SURMOUNT-5, the first head-to-head trial, adults without diabetes lost 20.2% of body weight on tirzepatide versus 13.7% on semaglutide over 72 weeks (Aronne et al., NEJM 2025). Semaglutide has the longer track record and dedicated cardiovascular outcome data from the SELECT trial. Side effects are similar, so cost, coverage, tolerance and medical history often decide which one a prescriber chooses.

Is compounded semaglutide the same as Wegovy?

Compounded semaglutide is not the same as Wegovy. Wegovy is an FDA-approved product made under federal manufacturing standards, while compounded versions are mixed by pharmacies, are not FDA approved, and are not reviewed for safety, effectiveness or quality. The FDA declared the semaglutide shortage resolved in February 2025, which narrowed when compounding is allowed. Anyone using a compounded product should confirm the pharmacy is state licensed and, ideally, PCAB accredited.

Do you have to take GLP-1 medication forever?

Many people need to stay on a GLP-1 medication long term to keep the weight off. In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year, and blood pressure and blood sugar improvements faded too. Some patients taper to a lower maintenance dose, but evidence for tapering and intermittent dosing is still thin, so the decision belongs with the prescriber.

Does Medicare pay for Wegovy or Zepbound for weight loss?

Medicare covers certain GLP-1 drugs for weight loss through the Medicare GLP-1 Bridge, which runs from July 1, 2026, to December 31, 2027. Eligible people with Part D coverage can get Foundayo, Wegovy injection or tablets, or the Zepbound KwikPen with prior authorization for a $50 monthly copay, according to Medicare.gov. Part D plans can also cover Wegovy for heart risk reduction and Zepbound for sleep apnea.

Related Reading

• Metabolic Health: The Complete Guide (Pillar)
• Metabolic Syndrome: Can It Be Reversed Without Medication?
• Insulin Resistance: Early Signs and What to Do About Them
• GLP-1 Agonists and Inflammation: What the Research Shows
• PCOS Treatment Options: Evidence-Based Approaches

Sources

1. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155 ↩
2. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi:10.1111/dom.12932 ↩
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 ↩
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 ↩
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 ↩
6. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. doi:10.1056/NEJMoa2302392 ↩
7. Storgaard H, Cold F, Gluud LL, Vilsboll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):906-908. doi:10.1111/dom.12885 ↩
8. Conte C, Cecere A, Corradi F, et al. Muscle mass and fat mass changes with GLP-1 receptor agonist therapy: a systematic review and meta-analysis. Obesity. 2024;32(1):10-22. doi:10.1002/oby.23927 ↩
9. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725 ↩
10. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972 ↩
11. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394 ↩
12. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393:1796-1806. doi:10.1056/NEJMoa2511774 ↩
13. Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. doi:10.1056/NEJMoa2403664 ↩
14. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. doi:10.1056/NEJMoa2404881 ↩